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Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease affecting 
all organ systems. It affects primarily female patients in the reproductive age. The dis-
ease has a variable course from very mild to severe and may be fatal. It is characterized 
by exacerbations of disease activity called flares. Estrogens seem to be involved in SLE 
pathogenesis as they have multiple immunomodulating properties. In SLE the autoim-
mune process affects the neuroendocrine axis. Stress modulates disease expression 
in lupus patients. The disease affects the endocrine system. Hypothyroidism occurs 
in SLE patients in a higher rate than that of the general population. Hyperthyroidism 
is also observed in SLE, however, in the rate expected for the general population. 
Hashimoto’s thyroiditis is observed in SLE in a higher rate than that of the general 
population. Hyperparathyroidism is also observed in SLE, primary and secondary in 
the context of renal insufficiency due to lupus nephritis. Addison’s disease is rare in 
SLE. Cushing’s disease due to an adrenal adenoma has been observed, but it is rare. 
Ovarian function may be compromised in SLE, due to autoimmune oophoritis or 
drug toxicity. The recognition of endocrine disease in SLE is important as it may guide 
proper management and symptom amelioration.
Keywords: systemic lupus erythematosus, estrogens, neuroendocrine axis, stress, 
hypothyroidism, hyperthyroidism, Hashimoto’s thyroiditis, hyperparathyroidism, 
ovarian function
1. Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease affect-
ing all organ systems [1]. It affects mainly joints, skin, blood vessels, heart, lung, 
kidneys, liver and the nervous system [2]. It is the prototype of systemic autoimmune 
diseases. In patients with SLE the immune system attacks tissues and cells leading to 
inflammation and damage [3]. The course of SLE is variable, and maybe either mild 
or severe leading sometimes to fatal damage and death [4]. The disease is character-
ized by periods of exacerbation, which are called flares and periods of remission [5]. 
SLE occurs nine times more often in the female gender mainly in the reproductive 
age, and it is more frequent in people of non-European descent [6]. Different types of 
autoantibodies are present in SLE patients [7]. The B lymphocyte is believed to play a 
major pathogenic role in the disease and many different autoantibodies are detected, 
therefore the disease is classified as a “B-cell disease” [8, 9]. However, T lymphocytes 
also play a role in the immunopathogenesis of SLE [10]. Because of the presence of 
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many different autoantibodies, SLE is classified as a “B-cell disease.” Patients with 
SLE present with symptoms and inflammatory involvement that can affect virtually 
every organ [11]. The main features of SLE include the production of antinuclear 
antibodies and the deposition of immune complexes in basement membranes 
throughout the body where they induce an inflammatory response [12, 13]. Genetic, 
epigenetic, and environmental factors contribute to the development of this autoim-
mune process. Endocrine manifestations as expected also occur in patients with 
systemic lupus erythematosus [14] (Figure 1). Hypothyroidism has been observed 
in a higher rate than that expected in the general population. Hyperthyroidism has 
also been observed. Autoimmune Hashimoto’s thyroiditis has been observed in a 
higher rate than that expected in the general population. Graves’ disease has been 
observed in patients with SLE. Hyperparathyroidism has been observed in patients 
with SLE, mainly in the context of lupus nephritis. Hypoparathyroidism has also 
been observed. Autoimmune oophoritis leading to ovarian failure has been observed 
in patients with SLE. Despite the multisystem nature of the disease, it appears that it 
respects the adrenals, so that Addison’s disease is extremely rare in SLE.
2. The neuroendocrine axis in systemic lupus erythematosus
SLE is a systemic autoimmune disease characterized by a loss of self-tolerance 
[15]. The immune system is activated in the disease and pro-inflammatory cyto-
kines are secreted [16]. The immune system and the neuroendocrine system are 
interconnected [17]. The two systems interact in a bidirectional manner (Figure 2). 
During the autoimmune inflammatory response cytokines released from immune 
cells affect the neuroendocrine axis [18, 19]. In turn the neuroendocrine system 
secretes hormones which modulate the immune response [20].
The main target of activation by cytokines is the hypothalamic–pituitary–
adrenal (HPA) axis. Interleukin (IL) -1a and -1b, IL-6 and tumor necrosis factor 
(TNF)-a, which are released sequentially from macrophages upon activation, 
are powerful activators of the HPA axis. In vitro studies in isolated hypothalamic 
tissue have shown the ability of IL-1a, IL-1b, IL-6, IL-8 and TNF-a to initiate the 
release of corticotropin-releasing hormone (CRH) [21, 22]. In humans, a blunted 
HPA axis response to stimulation with hypoglycemia or CRH was shown in sev-
eral autoimmune diseases, including rheumatoid arthritis, Sjogren’s syndrome, 
fibromyalgia and SLE [23]. However, the relationship between HPA axis reactivity 
Figure 1. 
Common endocrine disorders in systemic lupus erythematosus.
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and inflammatory disease was challenged by experiments which showed that in 
high-stress situations, rats who had a robust corticosterone-response to stress 
developed more severe inflammation than rats who had a less profound corticoste-
rone response [24]. Differences in the HPA axis response to stress may discriminate 
patients who seem to have the same disease, but may have different responses to 
treatment [25]. The HPA axis in important in regulating disease severity in SLE. 
However, the development of the disease may alter the HPA axis response.
Prolactin (PRL) is a peptide hormone produced by the anterior pituitary. PRL 
can be produced by lymphocytes, which in turn express PRL receptors [26, 27]. 
Thus, PRL may have immunomodulatory functions [27–29]. Increased PRL levels 
have been observed in male and female patients with lupus [30, 31]. Furthermore, 
suppression of PRL secretion with bromocriptine provides beneficial effects in 
murine lupus and possibly in lupus patients [32]. Treatment with PRL breaks 
tolerance and induces a lupus like illness in autoimmune mice. PRL is in effect also 
a cytokine [29]. PRL receptors are distributed in the immune system [33]. Mild and 
moderate hyperprolactinemia has been demonstrated in 20–30% of SLE patients 
and was associated with active disease. Hyperprolactinemia may have a role in 
lupus nephritis and CNS involvement of patients who have SLE [34]. Elevated PRL 
levels were associated with increased disease activity in SLE and prolactin may 
have a pathogenic role in SLE [35]. Thus, PRL, a peptide hormone derived from 
the anterior pituitary gland and lymphocytes participates in the regulation of the 
immune response, stimulates immune cells and belongs to a network of immune 
endocrine interaction. Hyperprolactinemia has been found in SLE and PRL may 
participate in SLE activation during pregnancy [35]. High levels of prolactin may 
lead to the development or the exacerbation of an autoimmune disease such as SLE 
[36]. Prolactin is a bioactive hormone acting both as a hormone as well as a cytokine 
and it may act as an immunomodulator affecting the negative selection of autoreac-
tive B lymphocytes [29].
2.1 Stress and systemic lupus erythematosus
The adrenergic nervous system runs from the CNS to lymphoid organs, namely 
the thymus, spleen and lymph nodes. Its effects are mediated by noradrenaline 
which acts through the relevant receptors [37]. Noradrenaline receptors are 
expressed by immune cells, namely T and B lymphocytes and macrophages [38]. 
Noradrenaline and adrenaline stimulate IL-10 and transforming growth factor-b 
production, thus enhancing Th2 immunity [39, 40]. In SLE, a disease driven by 
Figure 2. 
The interaction between the neuroendocrine and immune systems in systemic lupus erythematosus.
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excess IL-10, disease activity may increase during states of high catecholamine 
release, such as acute stress. In a prospective study of patients with SLE, disease 
flares were associated with emotional stress or with the number or severity of daily 
stressors [41, 42]. Additionally, the effect of acute psychological stress induced 
differential immune response in SLE patients as compared to controls [43].
The hypothalamic–pituitary–adrenal axis responds to inflammatory cytokines 
[44]. It has been demonstrated that inflammatory cytokines, such as IL-1a and 
IL-1b, IL-6 and TNF-a are powerful activators of the hypothalamic–pituitary–adre-
nal axis [45, 46]. In SLE patients with central nervous system involvement elevated 
levels of inflammatory cytokines were observed in the cerebrospinal fluid [47] 
suggesting an involvement of these inflammatory cytokines in disease pathogenesis.
2.2 Estrogens in the pathogenesis of systemic lupus erythematosus
SLE is a disease affecting primarily female patients in the reproductive age [48]. 
Evidence exists implicating estrogens in the pathogenesis of SLE [49]. An extensive 
cross-talk takes place between estrogen and the immune system. Estrogens are a 
major modulating factor of the immune response [50] (Figure 3). Epidemiological 
evidence implicates estrogens in the pathogenesis of SLE, as during childhood 
where estrogen secretion is minimal the female: male ratio is 3:1 as opposed to 9:1 
in the reproductive age. In the postmenopausal period the ratio is 8:1 [51]. Evidence 
has shown that women with early menarche, or treated with oral contraceptives or 
hormone replacement therapy have an increased risk for SLE [52, 53]. The presence 
of the X chromosome appears also to be important for the pathogenesis of SLE. 
There appears to be a gene dose effect, as the prevalence of SLE in Klinefelter’s syn-
drome (XXY) is 14-fold that in the general male population, whereas it is decreased 
in female patients with Turner’s syndrome (XO) [54]. Pregnancy, in which the 
concentration of estrogens is extremely increased can cause a disease flare or even 
trigger the development of lupus [55, 56]. The puerperium is characterized by an 
increased risk for disease relapse [57]. Hormonal factors used for ovulation induc-
tion and in vitro fertilization may cause disease flare in SLE [52].
The main pathophysiologic processes of SLE are the loss of self-tolerance and 
the production of autoantibodies with consequent inflammatory response and 
organ injury [15]. Estrogens are capable of inducing these alterations in the immune 
system. Treg cells, immunosuppressive regulatory T cells, play an important role 
in the maintenance of self-tolerance and the prevention of autoimmunity. SLE 
Figure 3. 
The effect of estrogens on the immune system.
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patients have decreased numbers of Treg cells. Estradiol diminishes Treg cells 
[52, 58, 59]. In SLE, there is a switch from a type 1 (Th1) to a type 2 (Th2) T cell 
response where serum levels of Th2 cytokines, such as interleukin 4 (IL-4), IL-6, 
and IL-10, are elevated and there is decreased production of Th1 cytokines, such 
as IL-2 and interferon γ [60–62]. Estrogens alter Th1/Th2 ratio thus altering the 
balance between cellular and humoral immunity. Estrogens induce the development 
of Th2 lymphocytes and B cell hyperactivity leading to enhanced antibody produc-
tion [63]. Estrogens promote the life span of lymphocytes by decreasing apoptosis 
of T and B cells [64]. Thus, estrogens seem to play a key role in the development of 
autoimmunity. They suppress self-tolerance reducing Treg cells [65]. They alter the 
Th1/Th2 ratio, favoring the predominance of humoral immunity. They prevent the 
deletion of autoreactive B cells [66]. They induce the generation of autoantibodies 
and they stimulate the production of inflammatory cytokines [67].
3. Endocrine disorders in systemic lupus erythematosus
3.1 Thyroid disease in SLE
Autoimmune thyroid disease has been observed in patients with systemic lupus 
erythematosus, such as autoimmune Hashimoto’s thyroiditis, hypothyroidism and 
Graves’ disease.
3.1.1 Hypothyroidism
Hypothyroidism is observed in patients with SLE in a higher rate than in the 
normal population. In particular, Munoz and Isenberg [14] reported a rate of 
5.22% hypothyroidism, i.e. 37 patients, in their cohort of 708 patients with SLE 
in University College of London Hospital, as compared to 1–2% in the general UK 
population. In this cohort the onset of hypothyroidism occurred after the onset of 
SLE oftener. Other reports confirmed a higher than in the general population rate of 
hypothyroidism in SLE. In particular, Ong and Choy [68] in a Malaysian population 
of SLE patients observed a prevalence of hypothyroidism of 3.7%. Antonelli et al. 
[69] reported a prevalence of hypothyroidism of 4.5%. In an earlier report from the 
University College of London Hospital SLE cohort Pyne and Isenberg [70] reported 
a prevalence of hypothyroidism of 5.7%.
3.1.2 Hyperthyroidism
Hyperthyroidism is observed in patients with SLE. In their cohort of 708 
patients with SLE Munoz and Isenberg [14] observed a prevalence of hyperthyroid-
ism of 1.41% (10/708 SLE patients), similar to that in the general population [71]. 
Watad et al [72] and Ong et al [68] reported a prevalence of hyperthyroidism in 
SLE patients of 2.59% and 2.6%, respectively. Chan et al [73] observed a prevalence 
of 5.8% of hyperthyroidism in a study of 69 SLE patients. However, only 2.9% had a 
clinical hyperthyroidism.
3.1.3 Autoimmune Hashimoto’s thyroiditis
Autoimmune Hashimoto’s thyroiditis is frequently observed in patients with 
SLE. The prevalence of Hashimoto’s thyroiditis in patients with SLE as opposed 
to control subjects was investigated in a study [74]. The association of Hashinoto’s 
Hashimoto’s thyroiditis and anti-thyroid antibodies to the clinical, serological 
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profile and disease activity as well as cumulative organ damage in this group was 
also investigated. In a group of 301 SLE patients and 141 controls TSH levels, T4 
levels, antiTg antibodies and antiTPO antibodies were measured by chemilumi-
nescence and immunometric methods. The serological and clinical profile of the 
patients was reviewed. SLE disease activity was measured using the SLEDAI index. 
The prevalence of Hashimoto’s thyroiditis was 12.6% in SLE as opposed to 5.6% 
in controls, the difference being statistically significant. A lower prevalence of 
malar rash and a higher prevalence of anti-Sm was noted in lupus patients with 
Hashimoto’s thyroiditis. No association was noted between Hashimoto’s thyroid-
itis and disease activity of cumulative organ damage. In conclusion, a two-fold 
increased risk of Hashimoto’s thyroiditis was noted in lupus patients. In a study 
performed in China 63 cases of lupus patients who also had Hashimoto’s thyroiditis 
were studied [75]. Lupus patients were classified in four groups, those in remission, 
those with low disease activity, those with moderate and those with high disease 
activity. Free T3 levels were found to be negatively correlated with disease activ-
ity. In an effort to find a way to treat effectively Hashimoto’s thyroiditis and SLE a 
group of scientists [76] injected human amniotic epithelial cells in murine models 
of Hashimoto’s thyroiditis and SLE. They observed that levels of antiTg, antiTPO 
antibodies and TSH levels decreased as well as evidence of tissue destruction within 
the thyroid decreased. Additionally, the injection of human amniotic epithelial cells 
induced the disappearance of antidsDNA antibodies and ANA in mice with SLE and 
improved immunoglobulin profiles. It downregulated the ratio of Th17/Treg cells 
in both Hashimoto thyroiditis and SLE mice and upregulated the proportion of B10 
cells. Human epithelial amniotic cells suppressed the levels of pro-inflammatory 
cytokines, IL-17A and IFN-γ and enhanced TGF-β in the murine models of 
Hashimoto’s thyroiditis and SLE, thus suggesting a common pathogenic substrate in 
both diseases.
3.1.4 Graves’ disease
Graves’ disease is a systemic autoimmune disease with multiple manifestations, 
affecting the thyroid, the eyes and the skin [77]. Cases of Graves’ disease have been 
described in patients with SLE [78]. The case of a patient with Graves’ disease who 
later developed SLE has been described in the literature [79].
3.2 Pancreatic dysfunction in SLE pathogenesis and form
3.2.1 Diabetes mellitus 1
Cases of diabetes mellitus 1 have been described in SLE. In a cohort of SLE 
patients in the UK the prevalence of diabetes mellitus 1 was investigated [80]. The 
coexistence of diabetes mellitus 1, SLE and celiac disease has been described in a 
young female patient [81]. It appears that diabetes mellitus 1 is rare among SLE 
patients. However, the risk of developing renal disease, retinal disease and periph-
eral neuropathy requires careful follow up of the patients. It is also important for 
the physician to decide which complication is due to lupus or diabetes as the man-
agement is different.
3.2.2 Diabetes mellitus 2
Diabetes mellitus type 2 is reported with increasing frequency nowadays [82]. 
Hence, diabetes mellitus 2 has been reported in patients with SLE. In their cohort 
of 485 SLE patients Cortes et al. [80] reported 4 patients with diabetes mellitus 2 
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and two considered to have steroid induced diabetes mellitus. Thus, it appears that 
diabetes mellitus 2 is infrequent within lupus patients. This may be due to the fact, 
that lupus develops in a younger age than diabetes mellitus 2 [14]. The relationship 
between SLE and gestational diabetes has been studied in a meta-analysis [83]. 
It was found that SLE does not seem to increase the risk of gestational diabetes. 
However, steroid use in SLE may increase the risk of gestational diabetes.
3.3 Parathyroid disease in SLE
3.3.1 Hyperparathyroidism
Primary hyperparathyroidism is frequently recognized nowadays due to the 
routine measurement of serum calcium levels. Primary hyperparathyroidism has 
been reported in patients with lupus. However, there are just a few case reports 
in the literature of patients with SLE and primary hyperparathyroidism. Primary 
hyperparathyroidism due to the presence of a parathyroid adenoma in a 47-year 
old female patient with SLE has been described [84]. Hypercalcemia resolved in 
this patient after removal of the adenoma. Primary hyperparathyroidism due to a 
cystic parathyroid adenoma has also been described in a 62-year old female patient 
with SLE [85]. In their cohort of 708 lupus patients Munoz and Isenberg [14] also 
identified 5 (0.70%) patients with hyperparathyroidism, 1 with primary hyperpara-
thyroidism and 4 patients with secondary hyperparathyroidism in the context of 
chronic renal failure due to lupus nephritis. Hyperparathyroidism presented after 
lupus in all cases described.
3.4 Adrenal disease in SLE
3.4.1 Addison’s disease
Addison’s disease has been reported in patients with SLE. However, there are 
only a few case reports of Addison’s disease in patients with SLE. The case of a 
29-year old female patient who presented with Addisonian crisis in the presence of 
SLE and responded therapeutically to corticosteroids, both as far as Addison’s and 
lupus is concerned has been described [86]. In their cohort of lupus patients Munoz 
and Isenberg [14] did not identify any patient with Addison’s disease. It appears that 
Addison’s disease is a rare occurrence in lupus patients.
3.4.2 Cushing’s syndrome
The occurrence of Cushing’s syndrome due to an adrenal adenoma in patients 
with SLE is rare. The case of an 18-year old female patient with subclinical 
Cushing’s syndrome who developed lupus has been described [87]. The patient was 
successfully treated by surgical removal of the adrenal adenoma. A case of a 51-year 
old woman with SLE who developed Cushing’s syndrome and was found to have a 
left adrenal adenoma has been described [88]. The patient was successfully man-
aged by laparascopic left adrenalectomy.
4. Ovarian function
Reproductive function of young female patients with SLE is commonly per-
turbed by various pathophysiologic mechanisms [89]. Ovarian reserve is dimin-
ished even in the presence of mild lupus suggesting a direct effect of the disease 
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itself on ovarian function [90, 91] (Figure 4). It is possible that the underlying 
process is autoimmune oophoritis [92–94]. The clinical manifestations of these 
abnormalities are menstrual irregularity, amenorrhea, or premature ovarian failure. 
Menstrual irregularities are frequently observed in patients with SLE, and many of 
them are associated with the activity of the disease [95]. SLE itself induces dys-
function in the hypothalamic–pituitary-ovarian axis and elevates serum prolactin 
[35, 96, 97]. A study compared the levels of anti–müllerian hormone (AMH) as a 
marker of ovarian reserve between SLE patients and control subjects and found that 
SLE patients had significantly lower AMH levels than did the control subjects. No 
correlation was observed between disease activity and AMH levels [91]. Female SLE 
patients may have subfertility issues due to active disease, the use of immunosup-
pressive medications and delayed childbearing [98]. These findings show that SLE 
itself has a negative influence on ovarian reserve and function.
SLE patients presenting with severe manifestations of the disease are treated with 
the alkylating agent cyclophosphamide [99, 100]. Cyclophosphamide is toxic to the 
ovaries [101–103]. SLE patients exposed to cyclophosphamide have a much higher 
risk of developing premature ovarian failure and infertility as compared to those 
receiving less toxic agents [91, 95, 104]. Cyclophosphamide leads to a decrease in 
reproductive life span and possibly premature ovarian failure. If the loss of ovarian 
function develops during or shortly after the completion of therapy, it is termed 
acute ovarian failure. For those who retain ovarian function after the completion 
of chemotherapy, a subset will go on to develop premature menopause before the 
age of 40 [105]. The clinical manifestations of ovarian damage in women at repro-
ductive age vary from temporary irregular menses to amenorrhea, infertility, and 
premature ovarian failure depending on the magnitude of the damage. The prob-
ability of developing permanent ovarian failure depends on the following factors: 
patient’s age and the type, dose, and duration of the treatment. If the patient is 
older and her ovarian reserve is low, they are less likely to retain or regain menstrual 
function than younger ones. Studies have documented that cyclophosphamide 
administration is the most significant risk factor for ovarian failure and that AMH 
is a sensitive and reliable marker of ovarian reserve and damage after exposure to 
cyclophosphamide in female patients with SLE [106–108]. In the case of cyclophos-
phamide administration in lupus patients fertility preservation may be attempted 
[108]. Currently, embryo or oocyte freezing are the established methods used for 
fertility preservation in patients receiving gonadotoxic treatment [109–111]. Other 
Figure 4. 
Factors adversely affecting ovarian function in systemic lupus erythematosus.
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options are ovarian tissue freezing and the use of gonadotropin-releasing (GnRH) 
hormone agonist treatment concurrently with chemotherapy [112, 113].
In conclusion, the reproductive function of female SLE patients can be adversely 
affected by various mechanisms such as, the chronic inflammatory state, autoim-
mune ovarian disease in the form of autoimmune oophoritis, lupus flares associated 
with hyperprolactinemia, which may interfere with ovulation and may modulate 
immune activity and temporary or even permanent premature ovarian failure as a 
result of the administration of cytotoxic agents such as cyclophosphamide.
5. Conclusion
SLE is a systemic autoimmune disease which affects all organ systems and occurs 
frequently in female patients in the reproductive period. Estrogens appear to modu-
late the immune response, induce loss of self-tolerance, alter the Th1/Th2 balance 
in favor of the Th2 process, induce the survival of T and B lymphocytes and the 
production of autoantibodies. Estrogens appear to be involved in the pathogenesis of 
SLE. In SLE neuroendocrine system function is affected by the autoimmune process, 
the neuroendocrine system affecting in turn the disease process. Stress appears to 
affect disease expression in lupus patients. In SLE hypothyroidism occurs oftener 
than in the general population, hyperthyroidism occurs in the same rate as in the 
general population and Hashimoto’s thyroiditis is present oftener than in a control 
population. Diabetes mellitus 1 occurs sometimes, diabetes mellitus 2 occurs less 
frequently than in the general population. Hyperparathyroidism has been observed 
in lupus patients. Addison’s disease is extremely rare in lupus patients. Cushing’s dis-
ease occurs infrequently in lupus patients. The ovarian function is affected in female 
SLE patients. Primary ovarian failure may occur due to autoimmune oophoritis. 
Cyclophosphamide in SLE is used and its use may be accompanied by the develop-
ment of premature ovarian failure. The recognition of endocrine disease is important 
in SLE as symptoms may be similar to those of lupus, however management may be 
different. The recognition and treatment of an endocrine problem in SLE may guide 
treatment and lead to symptom amelioration and proper patient management.
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